To view this email as a web page, click here

Today's Rundown

Featured Story

Biden outlines ways to get COVID-19 vaccine to hesitant Americans as demand ebbs

By Robert King

President Joe Biden made a new goal of having 70% of Americans get their first dose of COVID-19 vaccine by the Fourth of July as his administration makes new strides to get shots to hard-to-reach areas.

read more

Top Stories

Eli Lilly faces employee complaints, FDA troubles at factory making COVID-19 drug: report

By Noah Higgins-Dunn

Employees at Eli Lilly's New Jersey manufacturing site filed a complaint against a factory executive that claimed the exec, who is tasked with quality control, altered FDA-required documents to appear more favorable, Reuters reports. Separately, the FDA also raised quality control issues at another Lilly facility in Indianapolis in March.

read more

HHS announces $250M in new funding to get COVID-19 vaccines to medically underserved areas

By Robert King

HHS is giving out $250 million to community-based providers and organizations to get COVID-19 vaccination doses to medically underserved areas.

read more

COVID-19 tracker: Canada OKs Pfizer shot for adolescents; Biden admin supports lifting IP rights for vaccines

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

Health Canada authorized the use of the Pfizer-BioNTech vaccine in adolescents aged 12 to 15, becoming one of the first countries to authorize the shot for that age group. The Biden administration will support lifting intellectual property protections for COVID-19 vaccines. And more headlines.

read more

AstraZeneca investors hit back at CEO Soriot's 2021 pay plan after COVID vaccine stumbles

By Angus Liu

Another year, another revolt against AstraZeneca CEO Pascal Soriot’s compensation. Proxy advisers Glass Lewis and Institutional Shareholder Services raised concerns over AZ’s proposal to increase the maximum bonus and equities Soriot can get for the second consecutive year.

read more

Adagio's COVID-19 antibody marches on to phase 2/3 after early data suggest 12 months of protection

By Annalee Armstrong

Adagio Therapeutics’ COVID-19 antibody drug could provide as much as 12 months of protection against infection with the coronavirus, according to an early-stage clinical trial, supporting advancement of the therapy to phase 2/3.

read more

UnitedHealth Group pledges $1M to India to assist with procuring oxygen concentrators amid worsening COVID outbreak

By Paige Minemyer

UnitedHealth Group is donating $1 million to combat the growing COVID-19 outbreak crisis in India, building on $1.5 million sent previously to the country.

read more

Oxford Nanopore raises $271M for sequencing tools amid IPO plans

By Andrea Park

The new financing brings Oxford Nanopore’s total funding since it was founded in 2005 to more than $1.1 billion.

read more

Publisher: Rebecca Willumson

Associate Publisher: Angelique Alcover

Advertise | Contact

Manage Your Subscriptions

Trouble with your subscription?
Contact Support

Privacy Policy

This email was sent to newsletter@newslettercollector.com as part of the Fierce Life Sciences email list